Novel Inhibitors of *Staphylococcus aureus* Virulence Gene Expression and Biofilm Formation

Yibao Ma¹, Yuanxi Xu¹, Bryan D. Yestrepsky², Roderick J. Sorenson², Meng Chen³, Scott D. Larsen²*, Hongmin Sun¹*

1 Department of Internal Medicine, University of Missouri, Columbia, Missouri, United States of America, 2 Vahlteich Medicinal Chemistry Core, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, United States of America, 3 Nanova, Inc., Columbia, Missouri, United States of America

**Abstract**

*Staphylococcus aureus* is a major human pathogen and one of the more prominent pathogens causing biofilm related infections in clinic. Antibiotic resistance in *S. aureus* such as methicillin resistance is approaching an epidemic level. Antibiotic resistance is widespread among major human pathogens and poses a serious problem for public health. Conventional antibiotics are either bacteriostatic or bacteriocidal, leading to strong selection for antibiotic resistant pathogens. An alternative approach of inhibiting pathogen virulence without inhibiting bacterial growth may minimize the selection pressure for resistance. In previous studies, we identified a chemical series of low molecular weight compounds capable of inhibiting group A streptococcus virulence following this alternative anti-microbial approach. In the current study, we demonstrated that two analogs of this class of novel anti-virulence compounds also inhibited virulence gene expression of *S. aureus* and exhibited an inhibitory effect on *S. aureus* biofilm formation. This class of anti-virulence compounds could be a starting point for development of novel anti-microbial agents against *S. aureus*.

**Introduction**

*Staphylococcus aureus* is a major human pathogen that causes skin, soft tissue, respiratory, bone, joint and endovascular infections, including life-threatening cases of bacteremia, endocarditis, sepsis and toxic shock syndrome [1]. Approximately 30% of humans are *Staphylococcus aureus* carriers without symptoms [2]. *S. aureus* is also one of the most common pathogens in biofilm related infections of indwelling medical devices which are responsible for billions in healthcare cost each year in the United States [3–8]. Bacteria can attach to the surface of biomaterials or tissues and form a multilayered structure consisting of bacterial cells enclosed in an extracellular polymeric matrix [9]. Bacteria in biofilm are particularly resistant to antibiotic treatment [10]. In addition to the difficulty of effectively inhibiting biofilm with conventional antibiotic therapy, treatment is further complicated by the rise of antibiotic resistance among staphylococci. In recent years, methicillin resistance in *S. aureus* is approaching an epidemic level [2,11–13].

The emergence of antibiotic resistance poses an urgent medical problem worldwide. Current antibiotics target a small set of proteins essential for bacterial survival. As a result, antibiotic resistant strains are subjected to a strong positive selection pressure. Inappropriate and excessive use of antibiotics have contributed to the emergence of pathogens that are highly resistant to most currently available antibiotics [14–16]. The novel approach of inhibiting pathogen virulence while minimizing the selection pressure for resistance holds great promise as an alternative to traditional antibiotic treatment [17]. The feasibility of such an approach was demonstrated for *Vibrio cholerae* infections when a novel small molecule was identified that prevented the production of two critical virulence factors, cholera toxin and the toxin coregulated pilus. Administration of this compound in *vivo* protected infant mice from *V. cholerae* [18]. In a similar proof-of-concept (POC) study, a small molecule inhibitor of the membrane-embedded sensor histidine kinase QseC was identified. The inhibitor exhibited in *vivo* protection of mice against infection by *Salmonella typhimurium* and *Francisella tularensis* [19].

In a POC study following the same paradigm, we have identified a chemical series of small molecules from a high throughput screen (HTS) that can inhibit expression of the streptokinase (SK) gene in group A streptococcus (GAS) [20]. We previously demonstrated that SK is a key virulence factor for GAS infection [21]. SK activates human plasminogen into an active serine protease that degrades fibrin, a critical component of blood clots and an important line of defense against bacterial pathogens [22,23]. Our novel SK gene expression inhibitor also inhibited gene expression of a number of important virulence factors in GAS. The lead compound demonstrated in *vivo* efficacy at protecting mice against GAS infection, further supporting the feasibility of this novel anti-virulence approach to antibiotic discovery [20].
We subsequently expanded our work on the novel antimicrobial agents in GAS to *S. aureus* and demonstrated that this class of compounds is capable of inhibiting *S. aureus* virulence, especially biofilm formation.

**Results**

**Identification of Small Molecules Inhibiting Staphylococcus aureus Biofilm Formation**

Sixty eight novel analogs of HTS lead GAS SK expression inhibitor CCG-2979 [20] were synthesized and demonstrated inhibitory effect on SK expression (manuscript in preparation). These compounds were tested for their effects on *S. aureus* Newman biofilm formation in polystyrene microtiter plates by the standard crystal violet staining method [24]. Two of these analogs, CCG-203592 and CCG-205363 (Figure 1A and 1B), demonstrated reproducible inhibition of biofilm formation. CCG-203592 reduced biofilm formation by 45.2±3.9% and CCG-205363 reduced biofilm formation by 27.8±8.1% at 20 μM.

Both CCG-203592 and CCG-205363 had demonstrated more potency than their lead compound CCG-2979 at inhibiting SK expression (Figure 1C and 1D) [20]. The effect of CCG-203592 and CCG-205363 on biofilm formation was further tested with *S. aureus* RN6390 strain which is widely used for studying biofilm formation [25,26]. RN6390 was treated with different concentrations of CCG-203592 and CCG-205363, and biofilm formation was measured to estimate the IC₅₀ of the compounds. Both compounds demonstrated encouraging inhibition potency with IC₅₀ = 2.42±0.14 μM for CCG-203592 (Figure 2A) and IC₅₀ = 6.96±0.76 μM for CCG-205363 (Figure 2B). The more potent CCG-203592 was chosen for further analysis.

The effect of CCG-203592 on *S. aureus* biofilm formation was further tested with more relevant clinical strains. RN6390 was derived from *S. aureus* RN1 that was originally isolated from a sepsis patient [27]. NRS294 and NRS235 are clinical isolates associated with native valve endocarditis in the Network on Antimicrobial Resistance in Staphylococcus aureus program (NARSA) collection. Native valve endocarditis is strongly associated with biofilms [28]. As a result, these clinical strains were used to test the anti-biofilm effect of CCG-203592. There was little biofilm formation by NRS235 while significant biofilm formation was observed with RN1 and NRS234 (Figure 3). Fifty μM CCG-203592 was able to inhibit biofilm formation of RN1 (65.4±2.3%) and NRS234 (70.2±3.6%) significantly (p<0.001).

**Validation of S. aureus Biofilm Inhibition on Silicone Surface**

In order to further characterize the effect of CCG-203592 on *S. aureus* biofilm formation, RN6390 was treated with different concentrations of CCG-203592 and biofilm formation on medical grade silicone was measured. Medical grade silicone is widely used

---

**Figure 1. Compound structures and effects on SK expression.** A) Structure of CCG-203592 B) Structure of CCG-205363 C) Effects of CCG-203592 on the production of SK activity. Normalized SK activity of GAS treated with CCG-203592 at concentrations from 0.5 to 50 μM (SK activity of culture media divided by OD₆₀₀ nm of bacteria culture, then normalized to the value for DMSO treated GAS which was defined as 100%). The data is presented as mean±standard error of means for a total of 9 samples (pooled from 3 independent experiments in triplicate). D) Effect of CCG-205363 on the production of SK activity. The value was presented as mean±standard error of means for a total of 9 samples (pooled from 3 independent experiments in triplicate).

doi:10.1371/journal.pone.0047255.g001
in implantable medical devices [29]. A dose-dependent inhibition of biofilm formation by CCG-203592 was also observed (Figure 4A). The minimum concentration at which significant inhibition was observed (1 \( \mu \text{M}, p < 0.02 \)) is similar to what was observed with the polystyrene microtiter plate assays.

Scanning electron microscopy (SEM) analysis was carried out to visualize the detailed architecture of biofilm. Bacterial cells on control wafers formed multilayered conglomerated clusters with numerous bacterial cells (Figure 4B). At the lowest concentration of CCG-203592 (1 \( \mu \text{M} \)), the silicone surface was covered with multilayered dense clusters of bacterial cells, similar to control samples. However, at 5 \( \mu \text{M} \) CCG-203592, the biofilm structure was disrupted and a significant part of the silicone surface was cleared of bacterial cells. Bacterial cell clusters were much less dense than that of control biofilm. At 50 \( \mu \text{M} \) CCG-203592, there were only small clusters of cells scattered on the surface.

Toxicity of CCG-203592 in \textit{S. aureus} and Mammalian Cells

The chemical series of compounds to which CCG-203592 belongs was developed as a class of novel anti-virulence agents that can inhibit bacterial virulence without inhibiting bacterial growth in order to minimize the chance of developing resistance [20]. The effect of CCG-203592 on \textit{S. aureus} RN6390 growth was therefore tested. Growth of RN6390 in the presence of 50 \( \mu \text{M} \) CCG-203592 was analyzed over a period of 10 hours. No significant difference was detected when bacteria were treated with CCG-203592 compared to DMSO control (Figure 5A).

Cytotoxicity of CCG-203592 to mammalian cells was also tested on HeLa cells. The cytotoxicity of CCG-203592 at concentrations of 3.125, 6.25, 12.5, 25, 50 and 100 \( \mu \text{M} \) was determined by the colorimetric MTT viability assay and compared to cell viability when treated with DMSO control (Figure 5B). Dose-response studies revealed that no significant cytotoxicity was detected by CCG-203592 up to a concentration of 50 \( \mu \text{M} \) (\( p > 0.46 \)). At 100 \( \mu \text{M} \), CCG-203592 displayed cytotoxic activity on HeLa cells and the cell survival rate was 66.4\( \pm \)3.9\% (\( p < 0.001 \)).

Inhibition of Gene Expression of \textit{S. aureus} Virulence Factors by CCG-203592

The chemical series of compounds represented by CCG-203592 was shown to inhibit gene expression in GAS [20]. As a result, we hypothesized that CCG-203592 might also inhibit gene expression in \textit{S. aureus}. A number of \textit{S. aureus} RN6390 genes were selected that were reported to play roles in \textit{S. aureus} virulence and biofilm formation (Table 1). Among the 15 genes tested, \textit{AgrA} and \textit{ebpS} demonstrated no significant changes of gene expression when treated with 50 \( \mu \text{M} \) CCG-203592 (Figure 6).
Figure 4. The effect of CCG-203592 on *S. aureus* biofilm formation on silicone wafer. A) RN6390 biofilm formation on medical grade silicone wafer at different concentrations as determined by OD_{595} nm reading of crystal violet stain solubilized by ethanol. The data is presented as mean±standard error of means for a total of 9 samples (pooled from 3 independent experiments in triplicate). * p<0.05, ** p<0.01. B) Scan electron microscopy representative images of RN6390 biofilm formation on silicone wafer treated with different concentrations of CCG-203592 from triplicate.
doi:10.1371/journal.pone.0047255.g004

Figure 5. The effect of CCG-203592 on *S. aureus* and mammalian cell viability. A) Growth curves for RN6390 in the presence of CCG-203592 (50 μM) (grey curve) or DMSO alone (dark curve) as determined by OD_{600} nm. The data is presented as mean±standard error of means for a total of 9 samples (pooled from 3 independent experiments in triplicate). B) HeLa cell viability (as determined by mitochondrial reduction of MTT substrate) in the presence of CCG-203592 at different concentrations normalized to the value for DMSO treated samples which was defined as 100%. The data is presented as mean±standard error of means for a total of 12 samples (pooled from 3 independent experiments in quadruplicate).
doi:10.1371/journal.pone.0047255.g005
Table 1. Virulence factor genes tested by Real time RT-PCR.

| Gene       | Function                                      | Primers                                                                 | Reference |
|------------|-----------------------------------------------|-------------------------------------------------------------------------|-----------|
| 16S rRNA   | Internal standard gene                        | F: CTGGTAGTCCACGGCGTAAAC R: CAGCGGGAGTGCTTAATGC                         | [71]      |
| icaA       | Polysaccharide intercellular adhesion/ polymeric N-acetylg glucosamine production | F: AACAGAGGGAAGCAAAGGCAACTC R: CAGTAGATCTGTGATCCAAACGAC                 | [35]      |
| dltD       | Esterification of teichoic acids with D-alanine| F: GTGCTGCTGTGCGAGTGTCAAT R: CTGCTGACGAGTCTTTGTC                      | [31,36]   |
| atlA       | Autolysin                                     | F: TGGCAGCAGATTTTGCCGACCTTCG R: TGGATCTGACACATCAGCAACGGAAC               | [32,37]   |
| Psmα operon| Phenol soluble modulins μ                   | F: ACCCATGTTAAGAAAGCTCTCCTGTG R: ATGCGTAGACCTGTGACATT                  | [52,72]   |
| SPA        | Surface and secreted protein for bacterial aggregation | F: GCCAACACGATGAACTCAACAA R: AGCTAGCCTTGGCTTGATCA                    | [38]      |
| lrgA       | Cell death and lysis                          | F: CGGTGCTTAAAGCCGAGTTAAGGCAGAA R: GCTGGTACGAAAGTAGAACAAATG           | [53]      |
| sdrD       | SD-repeat-containing protein                  | F : AGTACACAGTTCCGAGCAACTC R : TCGAGCTGTTGTCCTCTTTGTC                  | [41,42]   |
| sspB       | Cysteine protease                             | F: CCACGAAATTTGTTGTGCTAG R: AACGAAACGCGATACACTCTC                      | [44,73]   |
| SigB       | Gene expression regulator                     | F: TCACCGGTAGTTACCCGCTTCAGTC R: GTCCGAGGACCTCCGATGAC                   | [46]      |
| AgrA       | Gene expression regulator                     | F: AAGCATAGCCAGTGTTGTAACCA CTGACTGCACTTCAG                           | [74]      |
| RnnaII     | Gene expression regulator                     | F: GCACGGTTCAAGAAACTTCAATG R: AGGCGATCCCACTTTAAACCCATG                 | [46]      |
| CodY       | Gene expression regulator                     | F: AAGAGGGCGGTGAAAGCCGATAAAAGCGT R: TCGCGATTATAGGAGCGCTCCGTAC          | [53,56]   |
| ebpS       | Surface protein                               | F: TTTCCGTTGAAAGCCTGAAAGTG R: AAGCCGACAAACGCACTTCAG                    | [42]      |
| cidA       | Cell death and lysis                          | F: AGCGTATTTCCGGAAGACATTC R: TACCGTAACTTCGGTCAGAGAGCA                   | [54]      |
| Hla        | Alpha-Toxin                                   | F: CGAAACGAGGCTAAACCCTTT R: GAACGAAAGGATCCATTGCTGC                       | [51]      |

doi:10.1371/journal.pone.0047255.t001

Figure 6. The effect of CCG-203592 on expression of selected S. aureus genes. Real time RT-PCRs were performed at mid-logarithmic growth phase (ML), late logarithmic growth phase (LL) and stationary (S) phase. The values are presented as the fold of change of gene transcriptional level of samples treated with 50 μM CCG-203592 versus that of samples treated with DMSO as calculated by 2^(-ΔΔCt) method. The data is presented as mean±standard error of means for a total of 9 samples (pooled from 3 independent experiments in triplicate). * p<0.05, ** p<0.01.
doi:10.1371/journal.pone.0047255.g006
Other genes demonstrated significant changes of gene expression by CCG-203592 (Figure 6). Expression of icaA gene of the icaADBC operon that is responsible for polysaccharide intercellular adhesin (PIA) or polymeric N-acetyl-glucosamine (PNAG) production [30] was increased by 88.3 ± 30.2% (p < 0.02) at mid-logarithmic (ML) growth phase and decreased by 40.2 ± 13% (p < 0.05) at stationary (S) phase compared to control by treatment with 50 µM CCG-203592. Expression of dltD gene of the dlt operon that is involved in D-alanine incorporation into teichoic acids [31] was decreased by 20.6 ± 4.5% (p < 0.01) at S phase. Functional autolysin altA gene expression [32] was reduced by 51.7 ± 5.6% (p < 0.01) at S phase. Expression of fmt gene operon which produces phenol soluble modulins S (PSM1–4) peptides [33] was decreased by 71.6 ± 3.8% (p < 0.01) at S phase. Immunoglobulin G-binding protein A (SPA) gene expression was decreased by 68.1 ± 6.1% (p < 0.01) at ML phase, 56.2 ± 7.2% (p < 0.01) at late logarithmic (LL) growth phase and decreased by 50.6 ± 6.2% (p < 0.01) at S phase. Murein hydrolase regulator sigE gene expression was decreased by 66.7 ± 5.1% (p < 0.01) at LL phase and decreased by 85.6 ± 2.3% (p < 0.01) at S phase. SD-repeat-containing protein D (sdrD) gene expression was reduced by 62.6 ± 7.2% (p < 0.01) at S phase. Sigma B (sigB) gene expression was decreased by 73.5 ± 5.1% (p < 0.01) at S phase. RNAIII gene expression was reduced by 20.12 ± 4.5% (p < 0.01) at S phase. Gene repressor CodY expression was reduced by 32.7 ± 10.9% (p < 0.05) at S phase. The murein hydrolase regulator sigE gene expression was increased by 63.1 ± 27.2% (p < 0.05) at ML phase and 294.0 ± 58.7% (p < 0.01) at LL phase. The alpha-toxin (Hla) gene expression was decreased by 37.1 ± 3.8% (p < 0.01) at LL phase.

Discussion

In recent years, antibiotic resistance has become one of the biggest threats to public health. Conventional antibiotics aim to kill or inhibit the growth of bacteria, leading to a strong selective advantage for resistant pathogens. As a result, a new approach to developing antimicrobial agents has been proposed that entails targeting virulence of the pathogens without inhibiting their growth, thereby reducing or slowing the selection for resistance [17–20,34].

In our previous studies, we identified a novel chemical series of low molecular weight compounds that can inhibit expression of group A streptococcus virulence gene expression, leading to in vivo efficacy at protecting mice against GAS infection [20]. These compounds demonstrated little interference with GAS growth following the new approach above to develop novel antimicrobial agents [17–19,34]. In order to further improve the potency and pharmacokinetic properties of this class of anti-virulence compounds, we have been carrying out Structure Activity Relationship (SAR) studies by synthesizing and characterizing more compounds in this chemical series (manuscript in preparation). In an effort to test whether these anti-virulence compounds have broad spectrum efficacy against other gram positive pathogens, we tested their effects on S. aureus biofilm formation.

A total of 68 compounds (those that were active against GAS SK expression) from the SAR program were tested for effects on biofilm formation of S. aureus Newman strain. Two of the compounds, CCG-203592 and CCG-205363, demonstrated consistent inhibition of biofilm formation. These two compounds were further tested for their potency at inhibiting biofilm formation using the widely studied biofilm strain, RN6390. Both compounds demonstrated significant inhibition potency with IC50s in the low micromolar range.

Further studies with the more potent compound CCG-203592 also showed that the compound can inhibit biofilm formation of clinically associated strain RN1 and NRS234 and also inhibit biofilm formation on the surface of medical grade silicone which is widely used in medical devices such as catheters that are particularly prone to S. aureus biofilm-related infection [3,29]. Scanning electron microscopy analysis of biofilm on the surface of silicone wafers indicated that CCG-203592 able to disrupt the biofilm structure. At higher concentrations (≥5 µM), it actually prevented colonization of bacteria on major areas of the silicone surface.

The effect of CCG-203592 on S. aureus growth was also studied. CCG-203592 had no effect on bacterial growth, which is similar to its analogs’ lack of growth inhibition of GAS [20]. The cytotoxicity of CCG-203592 was also tested with HeLa cells. Human HeLa cells demonstrated good tolerance to treatment with CCG-203592. The result suggested that CCG-203592 has minimal to no cytotoxicity at a concentration (50 µM) that can inhibit 80% biofilm formation and also significantly inhibit the expression of a number of virulence factor genes.

The lead compound of this class of anti-virulence compounds was identified as a repressor of SK gene expression in GAS, and a structurally related analog altered gene expression of a number of virulence factors in GAS [20]. We thus hypothesized that CCG-203592 could also change gene expression of S. aureus virulence factors. Biofilm formation proceeds through multiple steps involving the initial attachment step in which bacterial cells bind to the surface, a maturation step in which bacteria will accumulate and proliferate on the surface to form mature biofilm structures and finally detachment of bacterial cells for dissemination to other colonization sites [7]. A number of genes have been reported to be involved in these steps of biofilm formation. Some of these genes were selected for evaluation of their susceptibility to gene expression inhibition by CCG-203592 using a real time RT-PCR approach.

The genes down-regulated or up-regulated by CCG-203592 are involved in biofilm formation at different stages of biofilm formation. The icaADBC operon encodes enzymes involved in biosynthesis of polysaccharide intercellular adhesin (PIA) or polymeric N-acetyl-glucosamine (PNAG) that plays important roles in biofilm formation [30]. Deletion of the ica locus significantly decreased S. aureus biofilm formation [35]. Down-regulation of icaA could decrease production of PIA/PNAG, leading to reduction of biofilm formation. Interestingly, icaA was up-regulated during ML phase, but down-regulated at S phase. The net outcome of the effect of CCG-203592 on icaA could result from the combined effect of the dynamic changes of gene expression.

The dltABCD operon encodes four proteins responsible for esterification of teichoic acids with D-alanine [31]. Deficiency in dltA results in a stronger negative net charge on the bacterial cell surface and defects in the initial binding of bacteria to the surface in biofilm formation [36]. Down-regulation of dltD in the same operon could have similar effects. Autolysin alA is a major peptidoglycan hydrolase that cleaves newly synthesized peptidoglycan components before they are incorporated into the cell wall [32]. Primary attachment of bacteria to surfaces is impaired in alA null mutants [32,37]. SPA gene was consistently down-regulated by CCG-203592 in all three phases tested, SPA is able to induce cell aggregation and biofilm formation [38]. sdrD is one of the microbial surface components recognizing adhesive matrix molecules (MSCRAMM) that play important roles in mediating
bacteria adhesion to host tissues and forming biofilm though the exact function of sdOD is unknown [39–42]. *sspB* encodes a cysteine protease that is regulated by *agr* system [43]. Inactivating *sspC* which is an inhibitor of *sspB*, enhances the attachment of bacteria to solid surfaces and biofilm formation, suggesting that *sspB* has positive effects on biofilm formation [44].

*SigB* is an alternative sigma factor that regulates a large regulon [45] and inactivating *SigB* decreases biofilm formation by *S. aureus* and increases RNAIII level [46]. RNAIII is a component of the *agr* quorum-sensing system which regulates gene expression in response to outside signals [47]. Inhibition of *agr* system is important for biofilm development and *agr* also mediates biofilm dispersal [48,49]. The influence of *agr* system on biofilm development is multifaceted and complicated, depending on experimental conditions [50]. Hla was shown to be required for *S. aureus* biofilm formation and deficiency in Hla caused defects in biofilm formation [51]. Taken together, down-regulating the above genes could negatively impact biofilm formation.

On the other hand, *phaC* operon encodes four short PSMs peptides (~20 amino acids) [33]. Deletion of *phaC* causes defects in formation of biofilm channels and biofilm detachment and regrowth which suggested that PSMs are important for biofilm maturation and detachment. Lack of PSMs led to increased biofilm volume and thickness [52]. The *bg* operon is responsible for inhibition of murein hydrolase activity of the CidA protein. Mutant inactivating *lgdAB* operon exhibits increased biofilm adherence and matrix-associated DNA, and forms biofilm with reduced biomass and defective structures compared to mature wild-type biofilm [53]. Interestingly, *CidA* was up-regulated during ML and LL phases which could generate similar phenotype as down-regulating *bg* [54]. However, mutations in both *bg* and *CidA* caused aberrant biofilm maturation, suggesting that imbalance in their gene expression could disrupt biofilm development [53]. These effects of CCG-203592 may increase biofilm formation, which could be outweighed by the effects of down-regulation of other genes by CCG-203592. As a result, the combined effect of all the affected genes by CCG-203592 may produce net decrease of biofilm formation.

Interestingly, CCG-203592 decreased the RNAIII level slightly, suggesting that up-regulation of RNAIII level by decreased *SigB* and *CodY* level was compensated by changes in other genes that may also regulate RNAIII level. *CodY* is another global gene regulator that represses *agr* and *icaADBC* operon [55]. Inhibition of *CodY* could have different effects on biofilm formation. Inactivating *CodY* could enhance biofilm formation in *S. aureus* strain SA564 and UAMS-1 [53], but reduce biofilm formation in high-biofilm-producing *S. aureus* isolate S30 [56].

More genes were affected by CCG-203592 at stationary phase than at growing phases. We also observed that an analog of CCG-203592 changed expression of more genes at stationary phase than at growing phases in GAS [20]. It was well known that expression patterns of many genes are changed at different growth phases. For example, depletion of glucose and change of pH after a long period of culture at stationary phase could impact the gene expression of *agr* system [57]. As a result, it is possible that CCG-203592 has different impacts on gene expression at different growth phases. In order to understand the mechanism of action of this novel anti-virulence compound, further studies on the impact of gene expression changes at different growth phases on biofilm formation are needed.

Of note, some of the genes that have been down-regulated also play important roles in staphylococcus virulence. SPA, Hla and PSMs are virulence factors [33,58-62] and *sspB* plays important roles in staphylococcus evasion and resistance to host defense [63]. Based on the gene profile changes by CCG-203592, down-regulation of these genes could lead to defects in biofilm formation at different stages and could also lead to diminished virulence.

In conclusion, this class of novel anti-virulence compounds demonstrates inhibitory effects on gene expression of multiple *S. aureus* virulence factors, especially genes known to be involved in biofilm formation, resulting in significant inhibition of biofilm formation. The compounds also inhibit SK gene expression in GAS, suggesting that this class of compounds could target a gene regulatory mechanism that is conserved between GAS and *S. aureus*. This class of compounds could be a starting point for development of novel anti-microbial agents against multiple pathogens.

**Materials and Methods**

**Bacterial Strains and Culture Conditions**

GAS strain UMAA2616 was derived from the M type 1 strain MGAS166 [64]. The laboratory bacterial strains *S. aureus* Newman and RN6390 were used in this study. *S. aureus* Newman, a human clinical strain isolated from a case of secondarily infected tubercular osteomyelitis [65], was kindly provided by Dr. Olaf Schneewind, University of Chicago. *S. aureus* RN6390 [66] is a strain derived from RN1 [67] which was isolated from a sepsis patient. *S. aureus* RN6390 were provided by NARRS, which is supported under NIAID, NIH Contract No. HHSN227200700055C. NRS234 and NRS235 are clinical isolates associated with native valve endocarditis from NARRS.

The UMAA2616 strain was grown in Todd-Hewitt broth containing 0.2% yeast extract (THY) (Difco, Detroit, MI) supplemented with 100 μg/ml streptomycin [21]. planktonic culture of *S. aureus* was grown in THY. The medium for growth of static biofilms was THY with 0.5% glucose. All bacterial cultures were incubated at 37°C.

**Synthesis of CCG-2979 Analogs**

CCG-203592 and CCG-205363 were synthesized in the Vahleich Medicinal Chemistry Core laboratory at the University of Michigan. The procedures will be described in a separate publication (manuscript in progress).

**SK Activity Assay**

The SK activity assay was described previously [20]. Briefly, overnight UMAA2616 culture was diluted 1:1000 into fresh THY medium containing different concentrations of CCG-203592, CCG-205363 or DMSO and grown at 37°C to an OD600 nm = 1.0 in triplicate. Twenty μl of culture supernatant was added to 100 μl phosphate buffered saline (PBS), 10 μl human plasma (Innovative Research, Novi, MI), and10 μl S2403 (1 mg/ml) (Diapharma group Inc., West Chester, OH) and incubated at 37°C for 2 hours. SK activity was measured by OD405 nm and calculated as the percentage of SK activity compared to a DMSO control UMAA2616 culture. The experiment was performed three times to obtain the mean and standard error of means for SK activity of each treatment.

**Biofilm Assay**

The biofilm assay was performed using 96-well polystyrene flat-bottom microtiter plate (TPP Techno Plastic Products AG, Trasadingen, Switzerland) or on medical-grade silicone wafers (Cardiovascular Instrument Corp, Wakefield, MA). Silicone wafers were placed in wells of 12-well polystyrene flat-bottom microtiter plate (TPP Techno Plastic Products AG, Trasadingen, Switzerland).
Overnight cultures of \textit{S. aureus} were diluted 1:200 with fresh sterile THY medium containing 0.5% glucose. For the screening of test compounds, wells of 96-well microtiter plates were filled with 200 µl aliquots of the diluted cultures with 20 µM CCG-2979 analogs or DMSO in triplicate. For estimating IC\textsubscript{50} (the half maximal inhibitory concentration), wells of 96-well microtiter plates were filled with 200 µl aliquots of the diluted cultures with different concentrations of CCG-203592, CCG-203583 or DMSO in triplicate. For testing the effect of CCG-203592 on biofilm formation of strains RN1, NRS234 and NRS235, 50 µl of each of the compounds with different concentrations of CCG-203592, DMSO were added into culture tubes (Fisher Scientific Co., Pittsburgh, PA), and then cultured overnight at 37°C in triplicate. Samples were collected by centrifugation at OD\textsubscript{595}nm=0.5 (corresponding to ML growth phase), 0.9 (LL growth phase) and overnight (S) phase. Experiments were repeated three times. RNA in \textit{S. aureus} cells was stabilized using RNAprotect Cell Reagent (Qiagen, Valencia, CA). \textit{S. aureus} cells were digested by lyostaphin (Sigma, St. Louis, MO). RNA was then isolated by Trizol (Invitrogen, Carlsbad, CA) according to the manufacture’s protocol. After RNA extraction, TURBO DNA-free kit (Ambion, Austin, TX) was used to remove residual DNA contamination in the RNA samples. The purified RNA was reverse transcribed using iScript\textsuperscript{TM} cDNA Synthesis Kit (Bio-Rad, Richmond, CA). cDNA samples were quantified by real time PCR using CFX96 Real-Time PCR Detection System (Bio-Rad, Richmond, CA) and the \(2^{-\Delta\Delta Ct}\) Method [70]. PCR primers for each tested genes were presented in Table 1. The expression levels of all selected genes were normalized using 18S rRNA as an internal standard [71].

**Statistical Analysis**

Experimental data were analyzed with SigmaPlot 11.2 software (Systat Software Inc. Richmond, CA). Standard curves analysis was performed to generate dose-response curves and calculate IC\textsubscript{50}. The results were presented as means±standard error of means (SDEM). Student’s \(t\) tests were performed. A \(p\) value of <0.05 was considered to be statistically significant.

**Acknowledgments**

The authors would like to acknowledge the University of Missouri's Electron Microscopy Core Facility for assistance in preparing and imaging specimens for this research. We would like to thank Dr. David Ginsburg for his insightful critique and discussions.

**Author Contributions**

Conceived and designed the experiments: HS SDL. Performed the experiments: YM YX BDY RJJS MC. Analyzed the data: HS SDL YM YX. Wrote the paper: HS SDL YM.

**References**

1. Loyy FD (1998) Staphylococcus aureus infections. N. Engl. J. Med. 339: 520–532.

2. Chambers HF, DeLeo FR (2009) Waves of resistance. Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7: 629–641.

3. Agarwal A, Singh KP, Jain A (2010) Medical significance and management of staphyloccocal biofilm. FEMS Immunol. Med. Microbiol. 58: 147–160.

4. Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial biofilms: a common cause of persistent infections. Science 284: 1318–1322.
Inhibitors of S. aureus Virulence and Biofilm
Inhibitors of S. aureus Virulence and Biofilm

66. Peng HL, Novick RP, Kreiswirth B, Kornblum J, Schlievert P (1988) Cloning, characterization, and sequencing of an accessory gene regulator (agr) in Staphylococcus aureus. J Bacteriol 170: 4365–4372.
67. Novick RP, Richmond MH (1965) Nature and Interactions of the Genetic Elements Governing Penicillinase Synthesis in Staphylococcus Aureus. J Bacteriol 90: 467–480.
68. Cramton SE, Gerke C, Gotz F (2001) In vitro methods to study staphylococcal biofilm formation. Methods Enzymol. 336: 239–255.
69. McGillivray SM, Tran DN, Ramadoss NS, Alumasa JN, Okamura CY, et al. (2012) Pharmacological Inhibition of the ClpXP Protease Increases Bacterial Susceptibility to Host Cathelicidin Antimicrobial Peptides and Cell Envelope-Active Antibiotics. Antimicrob Agents Chemother 56: 1854–1861.
70. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408.
71. Tan H, Peng Z, Li Q, Xu X, Guo S, et al. (2012) The use of quaternised chitosan-loaded PMMA to inhibit biofilm formation and downregulate the virulence-associated gene expression of antibiotic-resistant staphylococcus. Biomaterials 33: 565–577.
72. Queck SY, Jameson-Lee M, Villaruz AE, Bach TH, Khan BA, et al. (2008) RNAIII-independent target gene control by the agr quorum-sensing system: insight into the evolution of virulence regulation in Staphylococcus aureus. Mol. Cell 32: 150–158.
73. Rice K, Peralta R, Bast D, de Azavedo J, McGavin MJ (2001) Description of staphylococcus serine protease (ssp) operon in Staphylococcus aureus and nonpolar inactivation of sspA-encoded serine protease. Infect Immun 69: 159–169.
74. Beles BR, Thoendel M, Roth AJ, Horswill AR (2010) Identification of genes involved in polysaccharide-independent Staphylococcus aureus biofilm formation. PLoS One 5: e10146.